Osteochondrodystrophic lesions in chelated thalassemic patients: An histological analysis

被引:8
作者
De Sanctis, V
Stea, S
Savarino, L
Granchi, D
Visentin, M
Sprocati, M
Govoni, R
Pizzoferrato, A
机构
[1] Ist Ortoped Rizzoli, Dipartimento Putti, Bologna, Italy
[2] Arcispedale St Anna, Dept Pediat & Adolescent Med, Ferrara, Italy
关键词
thalassemia; histology; bone lesions; deferoxamine;
D O I
10.1007/s00223001121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Some patients affected by thalassemia major and treated with an iron-chelating drug such as deferioxamine can suffer from severe osteochondrodystrophic lesions of the long bones. These lesions were radiologically and clinically evident in 2.8% of the patients we examined over the last 10 years. The aim of our research was to evaluate the morphology and morphometry of five tibial biopsy specimens taken from thalassemic patients with bone lesions and two bone biopsy specimens taken from thalassemic patients with no alteration of the long bones. All the bone samples showed a similar morphostructure. Abnormal chondrocytes, alteration of cartilage staining pattern, irregular columnar cartilage, and lacunae in the cartilaginous tissue were revealed histologically. Osteoid thickness was either normal or slightly increased. Some bone trabeculae had microfractures and some had cartilagineous eases. In five cases, iron deposition was detectable by Perls' Prussian Blue staining. It can be concluded that even in patients without radiographic signs of lesions, seriously damaged columnar cartilage, altered bone mineralization, and microfractures are common.
引用
收藏
页码:134 / 140
页数:7
相关论文
共 28 条
[1]  
BENSO L, 1995, EUR J PEDIATR, V154, P205
[2]   DEFEROXAMINE-INDUCED BONE DYSPLASIA IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRILL, PW ;
WINCHESTER, P ;
GIARDINA, PJ ;
CUNNINGHAMRUNDLES, S .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (03) :561-565
[3]   EFFECT OF AGE AT THE START OF IRON CHELATION-THERAPY ON GONADAL-FUNCTION IN BETA-THALASSEMIA MAJOR [J].
BRONSPIEGELWEINTROB, N ;
OLIVIERI, NF ;
TYLER, B ;
ANDREWS, DF ;
FREEDMAN, MH ;
HOLLAND, FJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (11) :713-719
[4]  
Caruso-Nicoletti M, 1998, J PEDIATR ENDOCR MET, V11, P957
[5]   A multi-center safety trial of the oral iron chelator deferiprone [J].
Cohen, A ;
Galanello, R ;
Piga, A ;
Vullo, C ;
Tricta, F .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :223-226
[6]   Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine [J].
DeSanctis, V ;
Pinamonti, A ;
DiPalma, A ;
Sprocati, M ;
Atti, G ;
Gamberini, MR ;
Vullo, C .
EUROPEAN JOURNAL OF PEDIATRICS, 1996, 155 (05) :368-372
[7]  
DESANCTIS V, 1995, ACTA PAEDIATR, V411, P119
[8]  
DEVIRGILIIS S, 1988, J PEDIATR-US, V113, P661
[9]  
*EUR COMM STAND, 1989, 45001 EN EUR COMM ST
[10]   SPINAL DEFORMITIES IN DEFEROXAMINE-TREATED HOMOZYGOUS BETA-THALASSEMIA MAJOR PATIENTS [J].
HARTKAMP, MJ ;
BABYN, PS ;
OLIVIERI, F .
PEDIATRIC RADIOLOGY, 1993, 23 (07) :525-528